User profiles for Massimo Puoti
 | Massimo PuotiProfessor of Infectious Diseases School of Medicine University of Milano Bicocca Verified email at unimib.it Cited by 24165 |
[HTML][HTML] Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …
properties. This study evaluates the efficacy and safety of baricitinib in combination …
Statements from the Taormina expert meeting on occult hepatitis B virus infection
Occult hepatitis B virus (HBV) infection is one of the most challenging topics in the field of
viral hepatitis with its virological and clinical relevance being debated for more than 30 years. …
viral hepatitis with its virological and clinical relevance being debated for more than 30 years. …
A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma
The aim of the study was to assess whether co‐infection by hepatitis‐B virus (HBV) and
hepatitis‐C virus (HCV) is associated with a higher risk of developing hepatocellular carcinoma (…
hepatitis‐C virus (HCV) is associated with a higher risk of developing hepatocellular carcinoma (…
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Background and Aim: Decisions on public health issues are dependent on reliable
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …
epidemiological data. A comprehensive review of the literature was used to gather country‐specific …
[HTML][HTML] Update of the statements on biology and clinical impact of occult hepatitis B virus infection
In October 2018 a large number of international experts with complementary expertise
came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). …
came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
71 million chronically infected individuals worldwide. Clinical care for patients with HCV-…
[HTML][HTML] Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection
…, R Soto-Malave, K Kaita, M Puoti… - … England Journal of …, 2018 - Mass Medical Soc
Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel
Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant
comorbidities in the HIV population; overall, it affects one third of HIV-positive individuals [1]. …
comorbidities in the HIV population; overall, it affects one third of HIV-positive individuals [1]. …
